Результаты лечения дистрептазой у больных с хронической тазовой болезнью

Department of Obstetrics and Gynecology, State University of Medicine and Pharmacy "Nicolae Testemitanu"Introduction. Chronic pelvin pain is a major cause for the patients presenting for a gynecological examination. However, the etiology may be related to sexual transmited diseases. Aim. The improvement of chronic pelvin pain treatment with Distreptaza drug. Material and methods: Between February 2012-June 2012 a prospective observational study on 60 female with age 18-45 years old was conducted; patients came to our hospital for treatment A detailed questeionnaire was used covering clinical data, the gynecological disease had an impact on quality of life. In half of patients was administrated Distreptaza. Results: The patients who took distreptaza had a better and a quicker result in their treatment. Conclusion: 1. The lengh of treatment of patient with PID who took Distreptaza diminished; 2. As the present study has not revealed any adverse effects due the usage of Distreptaza, it can be recommended for administration in ambulatory conditions out of hospital.Введение. Хроническая тазовая болезнь является основной причиной обращаемости пациентов для гинекологического обследования. Этиологически хроническая тазовая болезнь может быть связана с болезнями, которые передаются половым путем. Цель. Повышение качества лечения хронической тазовой болезни с помощью препарата дистрептаза. Материал и методы. В феврале-июне 2012 г. было проведено проспективное исследование, участницами которого стали 60 женщин в возрасте 18-45 лет. Все пациентки были госпитализированы и детально обследованы клинически. В результате тщательного проведения опроса было выявлено отрицательное воздействие гинекологической патологии на качество их жизни. 30 пациенткам было назначено лечение дистрептазой. Результаты. У пациенток, которые принимали дистрептазу, наблюдался лучший и более быстрый терапевтический эффект. Выводы: 1. Продолжительность периода лечения пациенток с хронической тазовой болезнью, которые принимали дистрептазу, уменьшилась. 2. В результате исследования не было выявлено побочных действий после приема дистрептазы. Таким образом, можно рекомендовать использование данного препарата в условиях амбулаторного лечения

Challenges in QCD matter physics - The Compressed Baryonic Matter experiment at FAIR

Substantial experimental and theoretical efforts worldwide are devoted to explore the phase diagram of strongly interacting matter. At LHC and top RHIC energies, QCD matter is studied at very high temperatures and nearly vanishing net-baryon densities. There is evidence that a Quark-Gluon-Plasma (QGP) was created at experiments at RHIC and LHC. The transition from the QGP back to the hadron gas is found to be a smooth cross over. For larger net-baryon densities and lower temperatures, it is expected that the QCD phase diagram exhibits a rich structure, such as a first-order phase transition between hadronic and partonic matter which terminates in a critical point, or exotic phases like quarkyonic matter. The discovery of these landmarks would be a breakthrough in our understanding of the strong interaction and is therefore in the focus of various high-energy heavy-ion research programs. The Compressed Baryonic Matter (CBM) experiment at FAIR will play a unique role in the exploration of the QCD phase diagram in the region of high net-baryon densities, because it is designed to run at unprecedented interaction rates. High-rate operation is the key prerequisite for high-precision measurements of multi-differential observables and of rare diagnostic probes which are sensitive to the dense phase of the nuclear fireball. The goal of the CBM experiment at SIS100 (sqrt(s_NN) = 2.7 - 4.9 GeV) is to discover fundamental properties of QCD matter: the phase structure at large baryon-chemical potentials (mu_B > 500 MeV), effects of chiral symmetry, and the equation-of-state at high density as it is expected to occur in the core of neutron stars. In this article, we review the motivation for and the physics programme of CBM, including activities before the start of data taking in 2022, in the context of the worldwide efforts to explore high-density QCD matter.Comment: 15 pages, 11 figures. Published in European Physical Journal